← Leaderboards
Qing Zhang
Ut Southwestern Medical Center
$9,546,603
Attributed
$9,546,603
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,546,603 · 10
By mechanism
R01$8,303,398 · 6
R00$724,590 · 1
K99$270,432 · 1
R21$169,106 · 1
F32$79,077 · 1
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Chuo Chen$9,073,859
- Xuewu Zhang$8,675,924
- Jeffrey A Cadeddu$43,418
- Payal Kapur$5,256,250
- Xiaochen Bai$5,235,262
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMediatingReportingMalignant NeoplasmsProteinsIn VitroCell ProliferationTumor GrowthCellsIn VivoGenesSignal TransductionProcollagen-Proline DioxygenaseUbiquitin-Protein LigaseTumorigenesisOncogenicOverexpressionBreast Cancer CellMalignant Breast NeoplasmBindingFoundationsHydroxylationUbiquitinationTumor
Grant awards (28)
New Von Hippel Lindau (VHL) tumor suppressor signaling in renal cancer$530,349
R01 · FY2025 · CA · contact PI
Genome-wide CRISPR screening identifies critical regulators controlling ccRCC lung metastasis$521,579
R01 · FY2025 · CA · contact PI
Identification of DCLK2-TBK1 signaling axis as a potential therapeutic target in kidney cancer$469,848
R01 · FY2025 · CA · contact PI
A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer$427,721
R01 · FY2025 · CA · contact PI
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer$395,093
R01 · FY2025 · CA · contact PI
New Von Hippel Lindau (VHL) tumor suppressor signaling in renal cancer$546,349
R01 · FY2024 · CA · contact PI
Identification of DCLK2-TBK1 signaling axis as a potential therapeutic target in kidney cancer$446,286
R01 · FY2024 · CA · contact PI
A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer$406,336
R01 · FY2024 · CA · contact PI
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer$375,340
R01 · FY2024 · CA · contact PI
Identification of DCLK2-TBK1 signaling axis as a potential therapeutic target in kidney cancer$485,709
R01 · FY2023 · CA · contact PI
A New Histone H3 Modification Regulates Epigenetic Programming and Gene Expression in Breast Cancer$443,721
R01 · FY2023 · CA · contact PI
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer$387,190
R01 · FY2023 · CA · contact PI
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer$393,876
R01 · FY2022 · CA · contact PI
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer$424,972
R01 · FY2021 · CA · contact PI
BBOX1 is a Novel Oncogenic Driver in Triple Negative Breast Cancer$403,756
R01 · FY2021 · CA · contact PI
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer$424,123
R01 · FY2020 · CA · contact PI
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer$341,487
R01 · FY2019 · CA · contact PI
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer$57,339
R01 · FY2019 · CA · contact PI
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer$411,162
R01 · FY2018 · CA · contact PI
OTUB1 as a Novel Therapeutic Target in Kidney Cancer by Deubiquitinating HIF2alpha$169,106
R21 · FY2018 · CA · contact PI
Exploration of ZHX2 as a novel substrate of pVHL and an oncogenic driver of renal cancer$411,162
R01 · FY2017 · CA · contact PI
Role of the EglN2 Target FOXO3a in Breast Cancer$249,000
R00 · FY2015 · CA · contact PI
Role of the EglN2 Target FOXO3a in Breast Cancer$241,530
R00 · FY2014 · CA · contact PI
Role of the EglN2 Target FOXO3a in Breast Cancer$234,060
R00 · FY2013 · CA · contact PI
Role of the EglN2 Target FOXO3a in Breast Cancer$135,216
K99 · FY2012 · CA · contact PI
Role of the EglN2 Target FOXO3a in Breast Cancer$135,216
K99 · FY2011 · CA · contact PI
Role of EgIN2 Prolyl Hydroxylase in Mammary Tumorigenesis$27,367
F32 · FY2011 · CA · contact PI
Role of EgIN2 Prolyl Hydroxylase in Mammary Tumorigenesis$51,710
F32 · FY2009 · CA · contact PI